Latest ebit for ACBD: $-15K, below the sector sector average of $2.4T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest EBIT for ACBD is $-15K as of June 2026. That compares with $-140K in the prior-year period — up 89.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Annabidiol's historical trend and sector peers before judging valuation or financial health.
Over the past year, ACBD's EBIT moved from $-140K to $-15K — a 89.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Annabidiol's operating scale or balance-sheet position.
Against its sector companies, ACBD currently prints $-15K for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Annabidiol's growth, margins, and balance sheet.
A EBIT figure of $-15K for ACBD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.
After noting ACBD's EBIT ($-15K), review year-over-year change from $-140K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.